shutterstock_664142593_jonathan_weiss
Jonathan Weiss / Shutterstock.com
23 May 2019Americas

Eli Lilly releases generic insulin injection

Eli Lilly has released a generic insulin injection at half of the list price of its identical branded medicine to the US market.

The Insulin Lispro Injection is a generic version of its Humalog U-100 product, and will retail at $137.35 per vial and $265.20 for a package of five KwikPens, half the price of the branded drug.

The news comes after Eli Lilly committed to providing a cheaper alternative to the diabetes treatment in March this year in the face of criticism of pharmaceutical prices.

Pharmacists will be able to substitute the generic for Humalog prescriptions, a press release confirmed.

In the release, Eli Lilly’s senior vice president for Connected Care and Insulins, Mike Mason, said that the “availability of Lilly's Insulin Lispro Injection is important progress that helps more people afford their insulin”.

"Lilly will continue to work with health plans, wholesalers, employers and the government to work toward permanent solutions that will help every person with diabetes afford their medicines,” Mason added.

The generic “adds to our suite of solutions that help significantly lower the amount people pay until a more sustainable solution is achieved,” he said.

Did you enjoy reading this story?  Sign up to our free newsletters and get stories like this sent straight to your inbox.


More on this story

Americas
3 June 2019   American pharmaceutical company Eli Lilly has secured an exclusive licence for a non-opioid, non-addictive chronic pain treatment from Boston-based biotech company Centrexion Therapeutics.

More on this story

Americas
3 June 2019   American pharmaceutical company Eli Lilly has secured an exclusive licence for a non-opioid, non-addictive chronic pain treatment from Boston-based biotech company Centrexion Therapeutics.